169 related articles for article (PubMed ID: 37695905)
1. Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma.
Yousefi M; Andrejka L; Szamecz M; Winslow MM; Petrov DA; Boross G
Proc Natl Acad Sci U S A; 2023 Sep; 120(38):e2303224120. PubMed ID: 37695905
[TBL] [Abstract][Full Text] [Related]
2. Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma.
Yousefi M; Andrejka L; Winslow MM; Petrov DA; Boross G
bioRxiv; 2023 Feb; ():. PubMed ID: 36778226
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic context shapes the fitness landscape of tumor suppression.
Blair LM; Juan JM; Sebastian L; Tran VB; Nie W; Wall GD; Gerceker M; Lai IK; Apilado EA; Grenot G; Amar D; Foggetti G; Do Carmo M; Ugur Z; Deng D; Chenchik A; Paz Zafra M; Dow LE; Politi K; MacQuitty JJ; Petrov DA; Winslow MM; Rosen MJ; Winters IP
Nat Commun; 2023 Oct; 14(1):6422. PubMed ID: 37828026
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.
Yousefi M; Boross G; Weiss C; Murray CW; Hebert JD; Cai H; Ashkin EL; Karmakar S; Andrejka L; Chen L; Wang M; Tsai MK; Lin WY; Li C; Yakhchalian P; Colón CI; Chew SK; Chu P; Swanton C; Kunder CA; Petrov DA; Winslow MM
Cancer Res; 2022 Apr; 82(8):1589-1602. PubMed ID: 35425962
[TBL] [Abstract][Full Text] [Related]
5. Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice.
Rogers ZN; McFarland CD; Winters IP; Seoane JA; Brady JJ; Yoon S; Curtis C; Petrov DA; Winslow MM
Nat Genet; 2018 Apr; 50(4):483-486. PubMed ID: 29610476
[TBL] [Abstract][Full Text] [Related]
6.
Hayashi T; Desmeules P; Smith RS; Drilon A; Somwar R; Ladanyi M
Clin Cancer Res; 2018 Mar; 24(6):1436-1447. PubMed ID: 29127119
[No Abstract] [Full Text] [Related]
7. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.
McFadden DG; Politi K; Bhutkar A; Chen FK; Song X; Pirun M; Santiago PM; Kim-Kiselak C; Platt JT; Lee E; Hodges E; Rosebrock AP; Bronson RT; Socci ND; Hannon GJ; Jacks T; Varmus H
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6409-E6417. PubMed ID: 27702896
[TBL] [Abstract][Full Text] [Related]
8. Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
Tian HX; Chen ZH; Jie GL; Wang Z; Yan HH; Wu SP; Zhang SL; Lu DX; Zhang XC; Wu YL
Cancer Med; 2023 Jan; 12(1):396-406. PubMed ID: 35702826
[TBL] [Abstract][Full Text] [Related]
9. Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.
Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A
Hum Mutat; 2013 Feb; 34(2):330-7. PubMed ID: 23292961
[TBL] [Abstract][Full Text] [Related]
10. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
[TBL] [Abstract][Full Text] [Related]
11. A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo.
Rogers ZN; McFarland CD; Winters IP; Naranjo S; Chuang CH; Petrov D; Winslow MM
Nat Methods; 2017 Jul; 14(7):737-742. PubMed ID: 28530655
[TBL] [Abstract][Full Text] [Related]
12. Carcinogen-induced tumors in SFN-transgenic mice harbor a characteristic mutation spectrum of human lung adenocarcinoma.
Kim Y; Shiba-Ishii A; Ramirez K; Muratani M; Sakamoto N; Iijima T; Noguchi M
Cancer Sci; 2019 Aug; 110(8):2431-2441. PubMed ID: 31144406
[TBL] [Abstract][Full Text] [Related]
13. An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma.
Zewdu R; Mehrabad EM; Ingram K; Fang P; Gillis KL; Camolotto SA; Orstad G; Jones A; Mendoza MC; Spike BT; Snyder EL
Elife; 2021 Apr; 10():. PubMed ID: 33821796
[TBL] [Abstract][Full Text] [Related]
14. Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma.
Lee JJ; Park S; Park H; Kim S; Lee J; Lee J; Youk J; Yi K; An Y; Park IK; Kang CH; Chung DH; Kim TM; Jeon YK; Hong D; Park PJ; Ju YS; Kim YT
Cell; 2019 Jun; 177(7):1842-1857.e21. PubMed ID: 31155235
[TBL] [Abstract][Full Text] [Related]
15. A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer.
Cai H; Chew SK; Li C; Tsai MK; Andrejka L; Murray CW; Hughes NW; Shuldiner EG; Ashkin EL; Tang R; Hung KL; Chen LC; Lee SYC; Yousefi M; Lin WY; Kunder CA; Cong L; McFarland CD; Petrov DA; Swanton C; Winslow MM
Cancer Discov; 2021 Jul; 11(7):1754-1773. PubMed ID: 33608386
[TBL] [Abstract][Full Text] [Related]
16. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.
Zhang C; Zhang J; Xu FP; Wang YG; Xie Z; Su J; Dong S; Nie Q; Shao Y; Zhou Q; Yang JJ; Yang XN; Zhang XC; Li Z; Wu YL; Zhong WZ
J Thorac Oncol; 2019 Nov; 14(11):1912-1923. PubMed ID: 31446140
[TBL] [Abstract][Full Text] [Related]
17. Alveolar progenitor cells and the origin of lung cancer.
Sainz de Aja J; Dost AFM; Kim CF
J Intern Med; 2021 May; 289(5):629-635. PubMed ID: 33340175
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial
Hebert JD; Tang YJ; Andrejka L; Lopez SS; Petrov DA; Boross G; Winslow MM
bioRxiv; 2024 Mar; ():. PubMed ID: 38496564
[TBL] [Abstract][Full Text] [Related]
19. Gene aberrations for precision medicine against lung adenocarcinoma.
Saito M; Shiraishi K; Kunitoh H; Takenoshita S; Yokota J; Kohno T
Cancer Sci; 2016 Jun; 107(6):713-20. PubMed ID: 27027665
[TBL] [Abstract][Full Text] [Related]
20. Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization.
Bolan PO; Zviran A; Brenan L; Schiffman JS; Dusaj N; Goodale A; Piccioni F; Johannessen CM; Landau DA
Cell Syst; 2020 Jan; 10(1):52-65.e7. PubMed ID: 31668800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
